2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

Journal of Medicinal Chemistry

Volumn 50, Issue 1, 2007, Pages 40-64

  Kaila, Neelu ^a   Janz, Kristin ^a   Huang, Adrian ^a   Moretto, Alessandro ^a   DeBernardo, Silvano ^a   Bedard, Patricia W ^a   Tam, Steve ^a   Clerin, Valerie ^a   Keith Jr , James C ^a   Tsao, Desirée H H ^a   Sushkova, Natalia ^a   Shaw, Gray D ^a   Camphausen, Raymond T ^a,b   Schaub, Robert G ^a   Wang, Qin ^a  

^a PFIZER INC   (United States)

^b Adnexus Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLOROBENZYL) 3 HYDROXY 7,8,9,10 TETRAHYDROBENZO[H]QUINOLINE 4 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; PADGEM PROTEIN; PROTEIN INHIBITOR; PSI 697; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL SURFACE; CONTROLLED STUDY; DISEASE MODEL; DOG; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HIGH THROUGHPUT SCREENING; KNOCKOUT MOUSE; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ANALYSIS; THROMBOCYTE; THROMBOSIS; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID STENOSIS; DOGS; FIBRINOLYTIC AGENTS; HYDROXYQUINOLINES; INDOLES; LEUKOCYTE ROLLING; MALE; MICE; MICE, KNOCKOUT; P-SELECTIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846201207     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060631p     Document Type: Article

References (70)

1. McEver, R. P.; Cummings, R. D. Role of PSGL-1 binding to selectins in leukocyte recruitment. J. Clin. Invest. 1997, 100, S97-103.
2. Furie, B.; Furie, B. C.; Flaumenhaft, R. A journey with platelet P-selectin: the molecular basis of granule secretion, signaling, and cell adhesion. Thromb. Haemostasis 2001, 86, 214-221.
3. Lowe, B. Glycosylation in the control of selectin counter-receptor structure and function. Immunol. Rev. 2002, 186, 19-36.
4. Vestweber, D. Regulation of endothelial cell contacts during leukocyte extravasation. Curr. Opin. Cell Biol. 2002, 14, 587-593.
5. Ley, K. The role of selectins in inflammation and disease. Trends Mol. Med. 2003, 9, 263-268.
6. Coller, B. S. Leukocytosis and ischemic vascular disease morbidity and mortality: Is it time to intervene? Arterioscler., Thromb., Vasc. Biol. 2005, 25, 658-670.
7. Blann, A. D.; Nadar, S. K.; Lip, G. Y. H. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 2003, 24, 2166-2179.
8. Hope, S. A. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk Intern. Med. J. 2003, 33, 450-462.
9. Martins, P. da C.; van den Berk, N.; Ulfman, L. H.; Koenderman, L.; Hordijk, P. L.; Zwaginga, J. J. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler., Thromb., Vasc. Biol. 2004, 24, 193-199.
10. Huo, Y.; Ley, K. Adhesion molecules and atherogenesis. Acta Physiol. Scand. 2001, 173, 35-43.
11. Huo, Y.; Schober, A.; Forlow, B,; Smith, D. F.; Hyman, M. C.; Jung, S.; Littman, D. R. Weber, C.; Ley, K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med. 2003, 9. 61-67.
12. Burger, P. C.; Wagner, D. D.; Platelet P-selectin facilitates athersclerotic lesion development. Blood 2003, 101, 2661-2666.
13. Bienvenu, J. G.; Tanguay, J.-F.; Theoret, J.-F.; Kumar, A.; Schaub, R. G.; Merhi, Y.; Recombinant soluble P-selectin glycoprotein ligand-1-1g reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001, 103, 1128-1134.
14. Smyth, S. S.; Reis, E. D.; Zhang, W.; Fallon, J. T.; Gordon, R. E.; Coller, B. S.; et al. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 h after injury. Circulation 2001, 103, 2501-2507.
15. Myers, D.; Wrobleski, S.; Londy, F.; Fex, B.; Hawley, A.; Schaub, R.; Greenfield, L.; Wakefield, T. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb. Haemostasis 2002, 87, 374-382.
16. Eppihimer, M. J.; Schaub, R. G. P-selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler., Thromb., Vasc. Biol. 2000, 20, 2483-2488.
17. Gasser, M.; Waaga-Gasser, A. M.; Grimm, M. W.; Grimm, M. R.; Lenhard, M. S.; Krist-Van Holthe, J. E.; Laskowski, I.; Shaw, G. D.; Thiede, A.; Hancock, W. W.; Tilney, N. L. Selectin blockade plus therapy with low-dose sirolimus and cyclosporin a prevent brain death-induced renal allograft dysfunction. Am. J. Transplant. 2005, 5, 662-670.
18. Seekamp, A.; van Griensven, M.; Dhondt, E.; Diefenbeck, M.; Demeyer, I.; Vundelinckx, G.; Haas, N.; Schaechinger, U.; Wolowicka, L.; Rammelt, S.; Stroobants, J.; Marzi, I.; Brambrink, A. M.; Dziurdzik, P.; Gasiorowski, J.; Redl, H.; Beckert, M.; Khan-Boluki, J. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients - Results of a phase II clinical trial. Crit. Care Med. 2004, 32. 2021-2028.
19. (a) Alper, J. Searching for medicine's sweet spot. Science 2001, 291, 2338-2343.
20. (b) Kerr, K. M.; Auger, W. R.; Marsh, J. J.; Comito, R. M.; Fedullo, R. L.; Smits, G. J.; Kapelanski, D. P.; Fedullo, P. F.; Channick, R. N.; Jamieson, S. W.; Moser, K. M. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. 2000, 162, 14-20.
21. (a) Aydt, E.; Wolff, G. Development of synthetic pan-selectin antagonists: A new treatment strategy for chronic inflammation in asthma. Pathobiology 2003, 70, 297-301.
22. (b) Romano, S. J., Selectin antagonists: Therapeutic potential in asthma and COPD. Treat. Respir. Med. 2005, 4, 85-94.
23. Bendas, G. Inhibitors of membrane receptors involved with leukocyte extravasation. Mini-Rev. Med. Chem. 2005, 5, 575-584.
24. Slee, D. H.; Romano, S.; Yu, J.; Nguyen, T. N.; John, J. K.; Raheja, N. K.; Axe, F. U.; Jones, T. K.; Ripka, W. C. Development of potent noncarbohydrate imidazole-based small molecule selectin inhibitors with anti-inflammatory activity. J. Med. Chem. 2001, 44, 2094-2107.
25. Ohta, S. Y.; Inujima, Y,; Abe, M.; Uosaki, Y.; Sato, S.; Miki, I, Inhibition of P-selectin specific cell adhesion by a low molecular weight, noncarbohydrate compound, KF38789. Inflammation Res. 2001, 50, 544-551.
26. Schön, M. P.; Krahn, T.; Schön, M.; Rodriguez, M.-L.; Antonicek, H.; Schultz, J. E.; Ludwig, R. J.; Thomas M.; Zollner, T. M.; Bischoff, E.; Bremm, K.-D.; Schramm, M.; Henninger, K.; Kaufmann, R.; Gollnick, H. P. M.; Parker, C. M.; Boehncke, W.-H, Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Med. 2002, 8, 366-372.
27. Kaila, N.; Janz, K.; DeBernardo, S.; Bedard, P. W.; Camphausen, R. T.; Tam, S.; Tsao, D. H. H.; Keith, J. C., Jr.; Nickerson-Nutter, C.; Shilling, A.; Young-Sciame, R.; Wang, Q. Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J. Med. Chem. 2007, 1, 21-39.
28. Compound 1 showed less than 10% bioavailability in mice.
29. Sutherland, L. H.; Sloboda, A. E.; Child, R. G.; Poletto, J. F.; Powell, D. W. 2-Phenyl-4-quinoline carboxylic acids. U.S. Patent 1989/ 4847381, 1989.
30. Mederski, W.; Osswald, M.; Dorsch, D.; Wilm, C.; Schmitger, C. J.; Christadler, M. Endothelin receptor antagonists. U.S. Patent 1998/ 5731321, 1998.
31. (a) Hesson, D. P. Preparation of 2-phenyl-4-quinolinecarboxylates as antitumor agents. U.S. Patent 1987/4680299, 1987.
32. (b) Ackerman, N. R.; Jaffee, B. D.; Loveless, S. E.; Neubauer, R. H. Preparation of 4-quinolinecarboxylic acid derivatives as immunosuppressive agents. Eur. Patent 1989/339485 A1, 1989.
33. Kaila, N.; Debernardo, S. L.; Janz, K. M.; Camphausen, R. T.; Bedard, P. W.; Huang, A. Preparation of fused quinoline derivatives as selectin inhibitors. U.S. Pat. Appl. Publ. 2005101569 A1, 2005.
34. (a) Cragoe, E. J.; Robb, C. M.; Bealor, M. D. The synthesis of 3-hydroxycinchoninic acid and certain of its derivatives. J. Org. Chem. 1953, 18, 552-560.
35. (b) Cragoe, E. J.; Bealor, M. D.; Robb, C. M.; Ziegler, C.; Sprague, J. M. The synthesis of 3-hydroxy-2-phenylquinoline-4,8-dicarboxylic acid and certain of its derivatives. J. Org. Chem. 1953, 18, 561-569.
36. (a) Sandmeyer, T. Isonitrosoacetanilides and their condensation to form isatin derivatives. Helv. Chim. Acta 1919, 2, 234-242.
37. (b) Yang, K.; Campbell, B.; Birch, G.; Williams, V. E.; Lemieux, R. P. Induction of a ferroelectric Sc* liquid crystal phase by an atropisomeric dopant derived from 4,4′-dihydroxy-2,2′-dimethyl-6,6′- dinitrobiphenyl. J. Am. Chem. Soc. 1996, 118, 9557-9561.
38. (c) Marvel, C. S.; Hiers, G. S. Isatin. Org. Synth. 1925, V, 71-74.
39. Cook, J. W.; Loudon, J. D.; McCloskey, P. The chemistry of the mitragyna genus. J. Chem. Soc. 1952, 3904-3912.
40. Huo, S. Highly efficient, general procedure for the preparation of alkylzinc reagents from unactivated alkyl bromides and chlorides. Org. Lett. 2003, 5, 423-425.
41. Bischofberger, N.; Waldmann, H.; Saito, T.; Simon, E. S.; Lees, W.; Bednarski, M. D.; Whitesides, G. M. Synthesis and analogues of 1,3-dihydroxyacetone phosphate and glyceraldehyde 3-phosphate for use in studies of fructose-1,6-diphosphate aldolase. J. Org. Chem. 1988, 53, 3457-3465.
42. x-mimicking selectin inhibitors: Design, synthesis and crystal structure in complex with E-selectin. J. Med. Chem. 2005, 48, 4346-4357 and references therein.
43. 1/2 of 6 min). Compound 90 was not pursued due to very poor aqueous solubility. Compound 142 was not pursued due to stability issues under the Biacore assay conditions. The esters (103, 104, and 105) were not pursued because they generally have poor pharmacokinetic properties.
44. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem., Int. Ed. 1999, 38, 1784.
45. Lepre, C. A.; Moore, J. M.; Peng, J. W. Theory and applications of NMR-based screening. Pharm. Res. Chem. Rev. 2004, 3641-3675.
46. Compound 79 was discarded due to very poor solubility in the Biacore and NMR assay.
47. Ley. K.; Bullard, D. C.; Arbones, M. L.; Bosse, R.; Vestweber, D.; Tedder, T. F.; Beaudet, A. L. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J. Exp. Med. 1995, 181, 669-675.
48. Hicks, A. E. R.; Leppanen, A,; Cummings, R. D.; Mcever, R. P.; Hellewell, P. G.; Norman, K. E. Glycosulfopeptides modeled on P-selectin glycoprotein ligand 1 inhibit P-selectin-dependent leukocyte rolling in vivo. FASEB J. 2000, 16, 1461-1462.
49. x and PSGL-1. Cell 2000, 103, 467-479.
50. Kumar, A.; Villani, M. P.; Patel, U. K.; Keith, J. C,, Jr.; Schaub, R. G. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999, 99, 1363-1369.
51. Khor, P, S.; McCarthy, K.; Dupont, M.; Murray, K.; Timony, G. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J. Pharmacol. Exp. Ther. 2000, 293, 618-624.
52. Kogan, T. P.; Dupre, B.; Bui, H.; McAbee, K. L.; Kassir, J. M.; Scott, I. L.; Hu, X.; Vanderslice, P.; Beck, P. J.; Dixon, R. A. F. Novel synthetic inhibitors of selectin-mediated cell adhesion: Synthesis of 1,6-bis[3-(3- carboxymethylphenyl)-4-(2-a-D-mannopyranosyloxy)phenyl]hexane (TBC1269). J. Med. Chem. 1998, 41, 1099-1111.
53. Abraham, W. M.; Ahmed, A.; Sabater, J. R.; Lauredo, I. T.; Bowinnikova, Y.; Bjercke, R. J.; Hu, X.; Revelle, M. B.; Kogan, T. P.; Scott, I. L.; Dixon, R. A. F.; Yeh, E. T. H.; Beck, P. J. Selectin blockade prevents antigen-induced late bronchial responses and airway hyper-responsiveness in allergic sheep. Am. J. Respir. Crit. Care Med. 1999, 159, 1205-1214.
54. Langer, R.; Wang, M.; Stepkowski, S. M.; Hancock, W. W.; Han, R.; Li, P.; Feng, L.; Kirken, R. A.; Berens, K. L.; Dupre, B.; Podder, H.; Dixon, R. A. F.; Kahan, B. D. Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. J. Am. Soc. Nephrol. 2004, 15, 2893-2901.
55. Wang, K.; Zhou, Z.; Zhou, X.; Tarakji, K.; Topol, E. J.; Lincoff, A. M. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J. Am. Coll. Cardiol. 2001, 577-82.
56. Hayashi, S.; Watanabe, N.; Nakazawa, K.; Suzuki, J.; Tsushima, K.; Tamatani, T.; Sakamoto, S.; Isobe, M. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 2000, 102, 1710-1717.
57. Zhou, Z.; Penn, M. S.; Forudi, F.; Zhou, X.; Tarakji, K.; Topol, E. J.; Lincoff, M. A.; Wang, K. Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler., Thromb., Vasc. Biol. 2002, 22, 1598-1603.
58. Dong, Z. M.; Brown, A. A.; Wagner, D. D. Prominent role of P-selectin in the development of advanced atherosclerosis in Apo E-deficient mice. Circulation 2000, 101, 2290-2295.
59. Bedard, P. W.; Clerin, V.; Sushkova, N.; Darby, A.; DeBernardo, S.; Eppihimer, M. J.; Harding, K.; Janz, K.; Kaila. N.; Keith, J. C.; Tavares, J.; Schaub, R. G.; Shaw, G. D. A novel P-selectin inhibitor, 31, demonstrates positive activity following oral administration in rodent models of vascular inflammation. Proceedings of the International Society of Thrombosis and Haemostasis Meeting, Sydney, Australia, August 6, 2005. Manuscript for publication in preparation.
60. Clerin, V.; Resmini, C.; Darby, A.; Tavares, J.; Harding, K.; Wong, T.; Bedard, P.; Shaw, G.; Keith, J. C.; Kaila, N.; DeBernardo, S.; Janz, K.; Schaub, R. G. WAY-197697, a P-selectin antagonist, reduces atherosclerosis and intimal hyperplasia in animal models of vascular disease. Proceedings of the 77th American Heart Association Scientific Sessions 2004, New Orleans, LA, November 7-10, 2004. Manuscript for publication in preparation.
61. Myers, D. D.; Rectenwald, J. E.; Bedard, P. W.; Kaila, N.; Shaw, G. D.; Schaub, R. G.; Farris, D. M.; Hawley, A. E.; Wrobleaski, S. K.; Henke, P. K.; Wakefield, T. W. Decreased venous thrombosis with an oral inhibitor of P selectin J. Vasc. Surg. 2005, 42, 329-336.
62. Rewcastle, G. W.; Atwell, G. J.; Zhuang, L.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 1991, 34, 217-222.
63. Lisowski, V.; Robba, M.; Rault, S. Efficient synthesis of novel 3-(Het)arylanthranilic acids via a Suzuki cross-coupling reaction of 7-iodoisatin with (Het)arylboronic acids in water. J. Org. Chem. 2000, 65, 4193-4194.
64. Arndt, F. Diazomethane. Org. Synth. 1935, XV, 3-5.
65. Huo, S. Highly efficient, general procedure for the preparation of alkylzinc reagents from unactivated alkyl bromides and chlorides. Org. Lett. 2003, 5, 423-425.
66. Cragoe, E. J., Jr.; Robb, C. M. 3-Hydroxyquinoline. Org. Synth. 1960, 40, 54-60.
67. Thomas, A.; Jensen, T. A.; Liang, X.; Tanner, D.; Skjaerbaek, N. Rapid and efficient microwave-assisted synthesis of aryl aminobenzophenones using Pd-catalyzed amination. J. Org. Chem. 2004, 69, 4936-4947.
68. Goetz, D. J.; Greif, D. M.; Ding, H.; Camphausen, R. T.; Howes, S.; Comess, K. M.; Snapp, K. R.; Kansas, G. S.; Luscinskas, F. W. Isolated P-selectin glycoprotein ligand-1 dynamic adhesion to P- and E-selectin. J Cell Biol. 1997, 137, 509-519.
69. Sako, D.; Comess, K. M.; Barone, K. M.; Camphausen, R. T.; Cumming, D. A.; Shaw, G. D. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 1995, 83, 323-331.
70. Myszka D. G. Improving biosensor analysis. J. Mol. Recognit. 1999, 12, 279-284.